25
Venus Medtech (Hangzhou) Inc.
2500.HK · HKSE
$1.11 -3.07% (-$0.04)
1M -10.57%
Market Cap ¥423.8M
P/E Ratio -
Div. Yield -
ROE 21.55%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
97 /100
Cheap P/S 1.38x
P/B 0.24x
P/E N/A
Growth
0 /100
Declining Rev. growth 8.95%
Book val. growth 21.23%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 69.05%
Net margin 132.89%
FCF margin 108.26%
Quality
2 /100
Poor ROIC 14.98%
ROE 21.55%
Asset turnover 0.12x
Debt
69 /100
Low Debt/Equity 0.12x
Current ratio 2.77x
Int. coverage -19.39x
Stability
53 /100
Moderate Beta 1.11x
Rev. volatility 27.91%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about 2500.HK
Online
Sector
Healthcare
Industry
Medical - Specialties
CEO
Hou-Sen Lim
Employees
557
Headquarters
Hangzhou
Upcoming events
01 APR
Earnings
Upcoming earnings report